
FDA approves landmark pancreatic cancer drug that’s shown to improve survival
The Food and Drug Administration approved Rasonque (daraxonrasib) on August 26, 2026, marking the first targeted RAS-inhibitor therapy cleared for advanced pancreatic cancer. Manufactured by Revolution Medicines, the once-daily oral tablet is indicated for adults with metastatic pancreatic adenocarcinoma who previously received systemic therapy or cannot tolerate multi-agent chemotherapy. Approval...








